4.1 Article

Association of autonomic symptoms with presynaptic striatal dopamine depletion in drug-naive Parkinson's disease: An analysis of the PPMI data

Journal

AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL
Volume 216, Issue -, Pages 59-62

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.autneu.2018.09.005

Keywords

Parkinson's disease; Autonomic; Striatal; Dopamine transporter; DAT

Categories

Funding

  1. Michael J. Fox Foundation for Parkinson's Research
  2. AbbVie
  3. Avid
  4. Biogen
  5. Bristol-Myers Squibb
  6. Covance
  7. GE Healthcare
  8. Genentech
  9. GlaxoSmithKline
  10. Lundbeck
  11. Eli Lilly
  12. Merck
  13. Meso Scale Discovery
  14. Pfizer
  15. Piramal
  16. Roche
  17. Sanofi Genzyme
  18. Servier
  19. TEVA
  20. UCB

Ask authors/readers for more resources

While the involvement of the central and peripheral autonomic networks is thought to play an integral role in the development of autonomic symptoms in Parkinson's disease (PD), there is little evidence for an association between autonomic symptoms and striatal dopaminergic depletion. We compared dopamine transporter activity in striatal subregions with various autonomic symptoms covered by the SCOPA-AUT domains including gastrointestinal, urinary, cardiovascular, thermoregulatory, pupillomotor, and sexual symptoms in 418 untreated patients with PD. We found evidence for a dopaminergic association with only urinary symptoms. Moreover, dopaminergic denervation in the putamen but not in the caudate may underlie these symptoms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available